Cargando…
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
BACKGROUND: Abnormal autocrine fibroblast growth factor 19 (FGF19) production has been observed in several types of cancers, including hepatocellular carcinoma (HCC). In this study, we investigated the potential of serum FGF19 as a novel tumor marker of HCC based on a sandwich enzyme-linked immunoso...
Autores principales: | Maeda, Takahiro, Kanzaki, Hiroaki, Chiba, Tetsuhiro, Ao, Junjie, Kanayama, Kengo, Maruta, Susumu, Kusakabe, Yuko, Saito, Tomoko, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Ogasawara, Sadahisa, Suzuki, Eiichiro, Ooka, Yoshihiko, Nakamoto, Shingo, Nakagawa, Ryo, Muroyama, Ryosuke, Kanda, Tatsuo, Maruyama, Hitoshi, Kato, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849282/ https://www.ncbi.nlm.nih.gov/pubmed/31718608 http://dx.doi.org/10.1186/s12885-019-6322-9 |
Ejemplares similares
-
Long-term administration of Tolvaptan to patients with decompensated cirrhosis
por: Kanayama, Kengo, et al.
Publicado: (2020) -
Left gastric vein-based noninvasive test for esophageal varices: a same-day comparison of portal hemodynamic assessment with endoscopic appearance
por: Maruyama, Hitoshi, et al.
Publicado: (2018) -
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
por: Kanzaki, Hiroaki, et al.
Publicado: (2021) -
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
por: Ogasawara, Sadahisa, et al.
Publicado: (2020) -
Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis
por: Maruyama, Hitoshi, et al.
Publicado: (2017)